Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
Balance Sheet
Inspect the capital base behind the business.
Assets
$366.28M
FY 2025 · Annual
+40.5% YoYLiabilities
$17.28M
FY 2025 · Annual
-2.3% YoYEquity
$349.00M
FY 2025 · Annual
+43.6% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.41M | 35.1M | 25.56M | 58.21M | 197.53M |
| Short-term Investments | 182.75M | 167.82M | 210.66M | 182.81M | 154.77M |
| Net Receivables | 4.11M | 1.08M | 2.25M | 3.34M | 1.07M |
| Inventory | (473K) | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 5.17M |
| Total Current Assets | 226M | 207.52M | 242.2M | 249.92M | 357.48M |
| Property, Plant & Equipment (Net) | 7.37M | 15.97M | 12.39M | 9.58M | 7.07M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.09M | 1.09M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 542K | 2.1M | 3.1M | 1.21M | 1.74M |
| Total Non-current Assets | 9M | 19.17M | 15.5M | 10.8M | 8.8M |
| Total Assets | 235M | 226.69M | 257.69M | 260.72M | 366.28M |
| Account Payables | 4.79M | 3.64M | 2.76M | 1.16M | 1.59M |
| Short-term Debt | 0 | 2.6M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.71M | 934K | 0 | 0 | 0 |
| Other Current Liabilities | 4.71M | 5.34M | 396K | 463K | 258K |
| Total Current Liabilities | 19.2M | 16.73M | 13.68M | 11.04M | 13.05M |
| Long-term Debt | 0 | 0 | 0 | 0 | 4.04M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 197K | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.26M | 0 | 197K | 197K | 197K |
| Total Non-current Liabilities | 4.26M | 11.02M | 8.83M | 6.64M | 4.24M |
| Total Liabilities | 23.46M | 27.74M | 22.5M | 17.68M | 17.28M |
| Common Stock | 41K | 52K | 62K | 54K | 67K |
| Retained Earnings | (302.47M) | (412.34M) | (509.67M) | (519.4M) | (594.28M) |
| Accumulated OCI | (397K) | (797K) | (136K) | 130K | 174K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 211.54M | 198.94M | 235.19M | 243.03M | 349M |
| Total Debt | 0 | 13.42M | 10.82M | 8.63M | 6.44M |
| Net Debt | (35.41M) | (21.68M) | (14.74M) | (49.58M) | (191.09M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $50.3M |
| Short-term Investments | $283.1M |
| Receivables | $1.8M |
| Other Current | $3.6M |
| Total Current Assets | $338.7M |
| PP&E (Net) | $6.4M |
| Other Non-current | $1.7M |
| Total Non-current Assets | $8.1M |
| Total Assets | $346.8M |
Analysis
Selected assets total $346.8M for Latest. The largest visible component is Short-term Investments at $283.1M, about 81.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 425 | 425 filing | Nov 12, 2026 |
How much cash does FULC have?
Fulcrum Therapeutics, Inc. (FULC) reported $197.53M in cash and equivalents in fiscal 2025.
How much debt does FULC carry?
Fulcrum Therapeutics, Inc. (FULC) reported $6.44M of total debt, with net debt of -$191.09M.
Continue the stock analysis
Jump to another research area for this company.